Teva's ProAir Digihaler (Albuterol Sulfate 117 mcg) Inhalation Powder Receives FDA Approval for Asthma & COPD Patients Aged 4 Years or Older
Shots:
- The approval is based on filled sNDA by Teva to the US FDA assessing ProAir Digihaler in COPD and asthma patients treating bronchospasm
- The electronic device with built in sensors detects- records and stores all events and information that can be transmitted to a mobile application connected to the device by Bluetooth- further helping patients to consult with their healthcare providers
- · ProAir Digihaler is a combination of breath-activated and multi-dose dry powder inhaler with albuterol- indicated to treat or prevent of bronchospasm in patients- with its expected launch in 2019
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com